Marapharm Ventures (CSE:MDM; OTXQX:MRPHF) issued a comment on the staff notice sent by the Canadian Securities Administrators (CSA) regarding cannabis operators with interests in the US while listed in Canada.
As quoted in the press release:
“Marapharm’s management is pleased with the content of the notice and is encouraged that regulators are taking a disclosure-forward approach to what is a complex issue, especially given the differing legal status of cannabis from State to State, as well as its status as a scheduled narcotic from the Federal Governments vantage point. Marapharm feels that the US Federal Government does not intend to meaningfully alter the way that existing cannabis business is conducted within legal US jurisdictions and believe the absence of meaningful enforcement in those legal states that have opted for recreational and medical legalization is proof of this. Marapharm intends to continue to pursue opportunities that may arise in the U.S. and encourages investors to take comfort from recent developments and successes,” states Linda Sampson, Marapharm’s CEO.